Eastman Kodak 's (NYSE: KODK) bid to turn itself from a photography leader into a pharmaceutical company got a boost today after a government regulatory watchdog said the U.S. International Development Finance Corp. did nothing wrong in awarding the company a $765 million government loan to assist in the transformation.
This past summer an internal investigation cleared Kodak of any wrongdoing in awarding top executives millions of dollars in stock options just before announcing it had won the loan. The results of the investigation have investors thinking it's all full-speed ahead. They should probably think again .
Image source: Getty Images.
For further details see:
Kodak Gets a Boost as Regulatory Watchdog Finds No Loan Wrongdoing